Table 2.
Overall survival (OS) and recurrence-free survival (RFS) rates in 488 patients with BCLC stage B hepatocellular carcinoma (HCC), by treatment (TACE+LR vs. LR), January 2007 to December 2015.
| Rates | Treatment | P | |
|---|---|---|---|
| TACE+LR (n = 223) % | LR (n = 265) % | ||
| 1-year OS | 90.6 | 73.3 | <0.001 |
| 3-year OS | 61.7 | 43.5 | <0.001 |
| 5-year OS | 52.9 | 33.8 | <0.001 |
| 1-year RFS | 54.6 | 39.4 | <0.001 |
| 2-year RFS | 41.4 | 29.4 | 0.002 |
| 3-year RFS | 36.3 | 26.3 | 0.008 |
BCLC, Barcelona Clinic Liver Cancer; TACE, transarterial chemoembolization; LR, liver resection (hepatectomy).
Bold values provided in this table was that P value < 0.05, there was significant difference between the two groups.